Vanillin-Derived Amides for Sickle Cell Disease Treatment

Solution Overview

Problem

Current treatments for sickle cell disease, such as hydroxyurea and Endari, have limitations including variable patient response, side effects, and accessibility issues, with existing vanillin-based compounds exhibiting poor pharmacokinetic properties like rapid metabolism and low bioavailability, necessitating the development of new anti-sickling agents with enhanced stability and bioavailability.

Innovation Solution

Development of vanillin-derived compounds with modified alcohol moieties into aryl or alkyl amides and esters, and inorganic phosphate esters, which resist metabolism and bind strongly to the F helix of hemoglobin, increasing oxygen affinity and directly destabilizing sickled red blood cell polymers, thereby providing a sustained antisickling effect.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If vanillin-based compounds are used to treat sickle cell disease, then antisickling activity is achieved, but pharmacokinetic properties deteriorate due to rapid metabolism and low bioavailability

Engineering Contradiction:

Improveantisickling activityVSAvoidpharmacokinetic duration

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent modifies the chemical structure of vanillin-based compounds by converting the alcohol moiety into aryl or alkyl amides and esters, or inorganic phosphate esters. These structural parameter changes reduce metabolism and increase bioavailability, thereby extending the duration of antisickling activity while maintaining therapeutic efficacy.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention creates composite molecular structures by combining vanillin core with various amide, ester, or phosphate groups. These composite compounds exhibit improved pharmacokinetic properties compared to parent vanillin, achieving both sustained duration of action and maintained antisickling activity through the synergistic effects of different molecular components.

Inventive Principle:

Principle #40Composite materials

2Reliability

If vanillin-based compounds are used to treat sickle cell disease, then antisickling activity is achieved, but bioavailability deteriorates due to significant metabolism

Engineering Contradiction:

Improveantisickling activityVSAvoidbioavailability

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent modifies the chemical structure of vanillin-based compounds by converting the alcohol moiety into aryl or alkyl amides and esters, or inorganic phosphate esters. These structural parameter changes reduce metabolism and increase bioavailability, thereby extending the duration of antisickling activity while maintaining therapeutic efficacy.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If high doses of vanillin-based compounds are administered frequently, then therapeutic efficacy is maintained, but treatment complexity and patient burden increase

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidtreatment regimen simplicity

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent modifies the chemical structure of vanillin-based compounds by converting the alcohol moiety into aryl or alkyl amides and esters, or inorganic phosphate esters. These structural parameter changes reduce metabolism and increase bioavailability, thereby extending the duration of antisickling activity while maintaining therapeutic efficacy.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The new compounds demonstrate significantly improved pharmacologic activity with prolonged half-lives and increased bioavailability, achieving enhanced antisickling potency and reduced side effects, allowing for less frequent and lower doses while maintaining therapeutic efficacy.

Implementation Method 1

Schiff-base interaction between the compound's aldehyde group and the N-terminal valine amino group of a globin chains (Val1) exists in equilibrium between bound adduct complex and unbound Hb and free compound

Methodology Applied

Scientific EffectSchiff-base interaction: Chemical Bonding

Data Source

PatentUS11401241B2Aromatic aldehydes with sustained and enhanced in vitro and in vivo pharmacologic activity to treat sickle cell disease

Publication Date: 2022.08.02 THE CHILDRENS HOSPITAL OF PHILADELPHIA

AI summary

Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are based on vanillin which is chemically modified to increase bioavailability and activity, e.g. so that the compounds bind to the F helix of hemoglobin (Hb) and prevent adhesion of red blood cells (RBCs).